GAMMA Investing LLC Buys 974 Shares of Galapagos NV (NASDAQ:GLPG)

GAMMA Investing LLC grew its stake in shares of Galapagos NV (NASDAQ:GLPG) by 77.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,233 shares of the biotechnology company’s stock after acquiring an additional 974 shares during the quarter. GAMMA Investing LLC’s holdings in Galapagos were worth $61,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Primecap Management Co. CA boosted its stake in Galapagos by 0.7% during the 2nd quarter. Primecap Management Co. CA now owns 720,240 shares of the biotechnology company’s stock valued at $17,848,000 after purchasing an additional 5,000 shares during the last quarter. Finepoint Capital LP lifted its holdings in shares of Galapagos by 2.8% during the third quarter. Finepoint Capital LP now owns 557,762 shares of the biotechnology company’s stock valued at $16,058,000 after purchasing an additional 15,000 shares in the last quarter. Stonepine Capital Management LLC boosted its position in shares of Galapagos by 23.2% during the second quarter. Stonepine Capital Management LLC now owns 485,000 shares of the biotechnology company’s stock valued at $12,018,000 after buying an additional 91,366 shares during the last quarter. Millennium Management LLC increased its holdings in Galapagos by 5.3% in the 2nd quarter. Millennium Management LLC now owns 341,639 shares of the biotechnology company’s stock worth $8,466,000 after buying an additional 17,089 shares in the last quarter. Finally, Renaissance Technologies LLC grew its stake in shares of Galapagos by 1.6% in the second quarter. Renaissance Technologies LLC now owns 270,800 shares of the biotechnology company’s stock worth $6,710,000 after acquiring an additional 4,300 shares during the period. 32.46% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on GLPG. TD Cowen cut shares of Galapagos from a “strong-buy” rating to a “strong sell” rating in a report on Thursday. Kepler Capital Markets downgraded Galapagos from a “hold” rating to a “reduce” rating in a research note on Wednesday, November 20th. Finally, Royal Bank of Canada decreased their price target on shares of Galapagos from $32.00 to $30.00 and set a “sector perform” rating on the stock in a research report on Friday, November 1st. Three research analysts have rated the stock with a sell rating and six have issued a hold rating to the company’s stock. Based on data from MarketBeat.com, Galapagos presently has an average rating of “Hold” and a consensus target price of $30.75.

Galapagos Trading Down 8.9 %

Shares of GLPG opened at $25.65 on Monday. Galapagos NV has a 1-year low of $24.16 and a 1-year high of $40.34. The company has a 50-day moving average of $27.23 and a 200 day moving average of $27.51.

Galapagos Profile

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.